Feedback
Malignancy Risk Assessment, Pelvic Mass, OVA1
3000394
Ordering Recommendation

Assess risk of ovarian cancer in women who present with an adnexal mass.

Mnemonic
OVA1
Methodology
Electrochemiluminescent Immunoassay (ECLIA)/Fixed-Rate-Time Nephelometry
Performed
Varies
Reported
4-8 days
New York DOH Approval Status
This test is New York DOH approved.
Submit With Order
ARUP Consult®
Disease Topics
Specimen Required
Patient Preparation
 
Collect
Serum Separator Tube (SST). 
Specimen Preparation
Transfer 2.2 mL serum to an ARUP Standard Transport Tube. (Min: 1.1 mL) 
Storage/Transport Temperature
Refrigerated. Also acceptable: Frozen. 
Unacceptable Conditions
 
Remarks
 
Stability
Ambient: Unacceptable; Refrigerated: 8 days; Frozen: 9 weeks 
Reference Interval
By Report
Interpretive Data


Note
Biomarkers: CA-125 II, Apoliproprotein A1 (Apo A-1), Beta-2 Microglobulin (B2M), Transferrin, and Prealbumin.
Hotline History
View Hotline History
Components
Component Test Code*Component Chart NameLOINC
3000395EER Malignancy Risk, OVA111526-1
3000396Malignancy Risk, OVA1, Menopause Status
3000397Malignancy Risk, OVA1, CA-125 II10334-1
3000398Malignancy Risk, Pelvic Mass, OVA1Score62488-2
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.
Aliases

Performed at ASPiRA Labs, Inc